Newly activated UI Cancer Center Clinical Trials

Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

Sponsor: Arog Pharmaceuticals, Inc.
Principal Investigator: John Quigley, MD

Leave a reply

Your email address will not be published. Required fields are marked *